LOUISVILLE, CO--GlobeImmune, Inc. (GBIM) today announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term viral suppression with an oral antiviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results